deferiprone has been researched along with Osteoporosis in 6 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 5.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 1.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "With regard to bone resorption and remodeling markers, the urinary excretion of pyridinium crosslinks was higher in patients with thalassemia for HP fraction (p < 0." | 1.33 | Chelation therapy and bone metabolism markers in thalassemia major. ( De Sanctis, V; Fornasari, PM; Fortini, M; Gamberini, MR; Marconi, S; Pratelli, L; Verri, E; Zolezzi, C, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noureldine, MHA | 1 |
| Taher, AT | 1 |
| Haydar, AA | 1 |
| Berjawi, A | 1 |
| Khamashta, MA | 1 |
| Uthman, I | 1 |
| Ahmad, MF | 1 |
| Zakaria, NZ | 1 |
| Arsad, N | 1 |
| Chew, KT | 1 |
| Abu, MA | 1 |
| Shafiee, MN | 1 |
| Omar, MH | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Wu, KH | 1 |
| Chang, JS | 1 |
| Tsai, CH | 1 |
| Peng, CT | 1 |
| Pratelli, L | 1 |
| Verri, E | 1 |
| Fortini, M | 1 |
| Marconi, S | 1 |
| Zolezzi, C | 1 |
| Fornasari, PM | 1 |
| Gamberini, MR | 1 |
| De Sanctis, V | 1 |
| Klinz, C | 1 |
1 review available for deferiprone and Osteoporosis
| Article | Year |
|---|---|
Rheumatological complications of beta-thalassaemia: an overview.
Topics: Arthritis; beta-Thalassemia; Blood Transfusion; Connective Tissue Diseases; Deferiprone; Femur Head | 2018 |
5 other studies available for deferiprone and Osteoporosis
| Article | Year |
|---|---|
A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy.
Topics: beta-Globins; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Deferiprone; Female; Homozygote | 2019 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Chelation therapy and bone metabolism markers in thalassemia major.
Topics: Adult; Alkaline Phosphatase; beta-Thalassemia; Bone and Bones; Bone Resorption; Case-Control Studies | 2006 |
[Marked hemosiderosis in myelodysplastic syndrome].
Topics: Aged; Deferiprone; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Heart Failure; Hemosiderosis; | 1999 |